Pulsenmore

Pulsenmore EBITDA per Share

The EBITDA per Share of Pulsenmore (PLSM.TA) as of Oct 21, 2026 is -1.89 ILS. In the previous year, EBITDA per Share was -6.30 ILS — a change of -69.97% (higher).

EBITDA per Share

-1.89ILS

YoY

-69.97%

Last updated:

EBITDA per Share of Pulsenmore is 2025 -1.89 ILS. EBITDA per Share of Pulsenmore was 2024 -6.30 ILS. It decreases by -69.97% higher compared to the previous year.

The Pulsenmore EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-0.61 ILS
Jan 1, 2020
-1.99 ILS
Jan 1, 2021
-4.33 ILS
Jan 1, 2022
-7.09 ILS
Jan 1, 2023
-8.50 ILS
Jan 1, 2024
-6.30 ILS
Jan 1, 2025
-1.89 ILS
The Pulsenmore EBITDA per Share history
YEAREBITDA per ShareYoY
-1.89ILS-69.97%
-6.30ILS-25.92%
-8.50ILS+19.98%
-7.09ILS+63.77%
-4.33ILS+117.62%
-1.99ILS+227.06%
-0.61ILS—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Pulsenmore Stock analysis

What does Pulsenmore do? Pulsenmore Ltd. generates revenue through the sale of its two miniaturized ultrasound systems, PulseNmore ES and PulseNmore FC, designed for home use in remote clinical diagnosis. The PulseNmore ES targets pregnant women requiring regular ultrasound monitoring, while PulseNmore FC caters to women undergoing in vitro fertilization needing follicle size assessments. Both systems integrate with smartphones, enabling patients to conduct tests at home and share results online with healthcare providers. The company also monetizes through software delivery for its devices, enhancing user experience and data management. The primary buyers of PulseNmore ES are pregnant women seeking convenient, clinic-free monitoring, and healthcare providers managing prenatal care remotely. PulseNmore FC is purchased by women undergoing in vitro fertilization, often through fertility clinics or medical centers that recommend the device. These segments value the convenience of home-based diagnostics and seamless telehealth integration without requiring in-person visits. Pulsenmore Ltd. focuses on global markets for its portable ultrasound solutions, serving patients in remote or underserved areas who benefit from telehealth-enabled diagnostics. The company’s products are positioned as cost-effective alternatives to traditional clinic visits, appealing to both end-users and healthcare institutions aiming to reduce operational costs while maintaining patient care quality. Pulsenmore is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulsenmore stock

EBITDA per Share of Pulsenmore is -1.89 ILS in 2025.

EBITDA per Share of Pulsenmore changed from -6.30 ILS to -1.89 ILS, representing a -69.97% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Pulsenmore since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Pulsenmore

All Key Metrics — Pulsenmore